[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
October 9, 2018

Bisphosphonates for Patients Diagnosed With Multiple Myeloma

Author Affiliations
  • 1Morsani College of Medicine, Division of Evidence Based Medicine, Department of Internal Medicine, University of South Florida, Tampa
  • 2Evidence-Based Medicine and Comparative Effectiveness Research Program, Departments of Supportive Medicine and Hematology, City of Hope, Duarte, California
JAMA. 2018;320(14):1483-1484. doi:10.1001/jama.2018.13773
Abstract

Clinical Question  Among patients with multiple myeloma, is bisphosphonate therapy associated with lower rates of mortality, vertebral fractures, nonvertebral fractures, and skeletal-related events compared with placebo or no treatment?

Bottom Line  Among patients with myeloma, bisphosphonates were associated with lower rates of pathological fractures and skeletal-related events compared with placebo or no treatment. Direct meta-analysis showed no association between bisphosphonates and mortality. In network meta-analysis, zoledronate was associated with lower risk of mortality compared with placebo or no treatment.

×